To better understand the potential applications of immunotherapy in BRAF-mutant NSCLC, we analyzed the tumor mutation burden and the fraction genome altered between all three BRAF mutation classes using data from cBioPortal. This evidence concerns the gene BRAF and non-small cell lung carcinoma.